Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PARA
Paramount Global Class B
PARA
|
+$75M |
| 2 |
Chevron
CVX
|
+$59.9M |
| 3 |
GE HealthCare
GEHC
|
+$57.5M |
| 4 |
Applovin
APP
|
+$54.7M |
| 5 |
OKLO
Oklo
OKLO
|
+$52.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xcel Energy
XEL
|
+$137M |
| 2 |
Meta Platforms (Facebook)
META
|
+$61.8M |
| 3 |
Becton Dickinson
BDX
|
+$59.9M |
| 4 |
CRWV
CoreWeave
CRWV
|
+$57.1M |
| 5 |
Apple
AAPL
|
+$50.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 11.73% |
| 2 | Financials | 9.81% |
| 3 | Utilities | 8.63% |
| 4 | Technology | 7.6% |
| 5 | Industrials | 7.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
URG
1376
Ur-Energy
URG
$565M
| $40K | ﹤0.01% |
+37,636
| New | +$30K |
|
1377
Pacific Biosciences
PACB
$420M
| $32K | ﹤0.01% |
+25,573
| New | +$29.5K |
|
1378
ChargePoint
CHPT
$162M
| $30K | ﹤0.01% |
2,130
-223
| -9% | -$2.99K |
|
1379
Ocugen
OCGN
$471M
| $30K | ﹤0.01% |
+30,824
| New | +$25.6K |
|
1380
Agilon Health
AGL
$1.62B
| $27K | ﹤0.01% |
+466
| New | +$37.4K |
|
1381
GrafTech
EAF
$178M
| $26K | ﹤0.01% |
+2,715
| New | +$24K |
|
|
K
1382
PUT
DELISTED
Kellanova
K
| $24K | ﹤0.01% |
+300
| New | +$24.5K |
|
1383
Humacyte
HUMA
$178M
| $21K | ﹤0.01% |
10,081
-141,773
| -93% | -$272K |
|
|
IAUX
1384
i-80 Gold Corp
IAUX
$1.57B
| $20K | ﹤0.01% |
+33,872
| New | +$20K |
|
1385
SmartRent
SMRT
$274M
| $19K | ﹤0.01% |
+19,503
| New | +$17.4K |
|
|
GENVR
1386
Gen Digital Inc Contingent Value Rights
GENVR
| $19K | ﹤0.01% |
+2,420
| New | +$17K |
|
1387
Lineage Cell Therapeutics
LCTX
$273M
| $17K | ﹤0.01% |
+19,149
| New | +$11.4K |
|
1388
Lightwave Logic
LWLG
$954M
| $16K | ﹤0.01% |
+13,071
| New | +$13.7K |
|
1389
Chegg
CHGG
$90.8M
| $13K | ﹤0.01% |
+10,565
| New | +$9.77K |
|
1390
Ring Energy
REI
$386M
| $13K | ﹤0.01% |
+15,850
| New | +$13.4K |
|
1391
SES AI
SES
$201M
| $13K | ﹤0.01% |
+14,137
| New | +$11.9K |
|
1392
Central Garden & Pet Co
CENT
$2.78B
| $12K | ﹤0.01% |
339
-131,507
| -100% | -$4.65M |
|
1393
Lexicon Pharmaceuticals
LXRX
$1.02B
| $12K | ﹤0.01% |
+12,241
| New | +$7.93K |
|
1394
Atossa Therapeutics
ATOS
$25.3M
| $11K | ﹤0.01% |
+901
| New | +$10.8K |
|
1395
Blink Charging
BLNK
$86.2M
| $10K | ﹤0.01% |
+10,247
| New | +$8.18K |
|
1396
GoPro
GPRO
$116M
| $10K | ﹤0.01% |
+13,688
| New | +$8.89K |
|
1397
Leslie's
LESL
$5.63M
| $8K | ﹤0.01% |
973
-2,855
| -75% | -$37.6K |
|
1398
Energy Vault
NRGV
$691M
| $8K | ﹤0.01% |
11,302
-5,641
| -33% | -$4.56K |
|
1399
Veru
VERU
$45M
| $8K | ﹤0.01% |
+1,407
| New | +$7.9K |
|
1400
ProKidney
PROK
$336M
| $7K | ﹤0.01% |
+11,663
| New | +$9.08K |
|
Similar funds
Michael Gelband's Q2 2025 Portfolio in Review
As of Q2 2025, Michael Gelband held 2,093 positions worth $11.4B, up 13% from $10.1B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Michael Gelband deployed $528M of net new capital in Q2 2025, opening 704 new positions and adding to 330 existing holdings. Its largest new stake was Chevron: 424,949 shares worth $60.8M.
By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 13% a quarter earlier, followed by Financials and Utilities.
On the sell side, the largest reduction was Xcel Energy, an estimated $137M trimmed.
- Michael Gelband's largest Q2 2025 buy was Chevron: 424,949 shares worth $60.8M.
- Michael Gelband added most to Paramount Global Class B in Q2 2025, an estimated $75M increase.
- Michael Gelband's biggest Q2 2025 reduction was Xcel Energy, cutting an estimated $137M.
- Michael Gelband fully exited Meta Platforms (Facebook) in Q2 2025, selling an estimated $61.8M.
- Michael Gelband's ten largest holdings make up 25% of its $11.4B portfolio in Q2 2025.
- Michael Gelband opened 704 new positions and closed 687 in Q2 2025.
- Michael Gelband's portfolio value rose 13% quarter-over-quarter to $11.4B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.